UTILIZATION OF CK19 AND CD56 EXPRESSION IN DIFFERENTIATING MALIGNANT FROM BENIGN LESIONS OF THYROID
Fuente:
Zenodo
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Recurso digital |
| Publicado: |
Zenodo
2025
|
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1866901798727450624 |
|---|---|
| author | Dr. Hiba Jaleel |
| author_facet | Dr. Hiba Jaleel |
| contents | <p><strong><span lang="EN-US">BACKGROUND: </span></strong><span lang="EN-US">Thyroid cancer accounts for majority of the endocrine cancer and is showing a rising trend. Precise pathological diagnosis is essential for optimal management of thyroid tumours and to avoid unwanted complications. Though histopathology is the main stay of diagnosis, ancillary diagnostic markers may be helpful in some cases with overlapping features or diagnostic discrepancies. The purpose of this study was to evaluate the diagnostic value of CK19 and CD56 immunohistochemical staining in distinguishing between benign and malignant thyroid lesions.</span></p> <p><strong><span lang="EN-US">MATERIAL & METHODS: </span></strong><span lang="EN-US">A total of 36 cases of thyroid lesions from January 2021 and August 2022 were taken for the study. After histopathological analysis representative sections were subjected for IHC using CK19 and CD56. Statistical analysis was done to observe frequency and significance.</span></p> <p><strong><span lang="EN-US">RESULTS:</span></strong><span lang="EN-US"> Out of 36 cases taken for the study, 16 cases were malignant thyroid neoplasm and 20 cases were benign thyroid lesions. All the malignant cases included in the study were Papillary thyroid carcinoma, its variants and Non invasive follicular neoplasm of thyroid with papillary like nuclear features. The benign lesions included in the study were nodular goitre, adenomatoid nodule and follicular adenoma. CK19 was positive in 93.75% cases of malignant neoplasm. PTC and its variants showed loss of expression of CD56 in 81.25% of cases, while 75% cases of benign thyroid lesion showed positive staining for the same</span></p> <p><strong><span lang="EN-US">CONCLUSION</span></strong><span lang="EN-US">: It was found that CK19 was very specific but less sensitive marker to differentiate benign from malignant neoplasm and CD56 was more sensitive and specific as a marker of benign thyroid lesion. Hence, the use of these markers together could be a useful and reliable diagnostic approach for differentiating malignant from benign thyroid lesions.</span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_18066295 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | UTILIZATION OF CK19 AND CD56 EXPRESSION IN DIFFERENTIATING MALIGNANT FROM BENIGN LESIONS OF THYROID Dr. Hiba Jaleel <p><strong><span lang="EN-US">BACKGROUND: </span></strong><span lang="EN-US">Thyroid cancer accounts for majority of the endocrine cancer and is showing a rising trend. Precise pathological diagnosis is essential for optimal management of thyroid tumours and to avoid unwanted complications. Though histopathology is the main stay of diagnosis, ancillary diagnostic markers may be helpful in some cases with overlapping features or diagnostic discrepancies. The purpose of this study was to evaluate the diagnostic value of CK19 and CD56 immunohistochemical staining in distinguishing between benign and malignant thyroid lesions.</span></p> <p><strong><span lang="EN-US">MATERIAL & METHODS: </span></strong><span lang="EN-US">A total of 36 cases of thyroid lesions from January 2021 and August 2022 were taken for the study. After histopathological analysis representative sections were subjected for IHC using CK19 and CD56. Statistical analysis was done to observe frequency and significance.</span></p> <p><strong><span lang="EN-US">RESULTS:</span></strong><span lang="EN-US"> Out of 36 cases taken for the study, 16 cases were malignant thyroid neoplasm and 20 cases were benign thyroid lesions. All the malignant cases included in the study were Papillary thyroid carcinoma, its variants and Non invasive follicular neoplasm of thyroid with papillary like nuclear features. The benign lesions included in the study were nodular goitre, adenomatoid nodule and follicular adenoma. CK19 was positive in 93.75% cases of malignant neoplasm. PTC and its variants showed loss of expression of CD56 in 81.25% of cases, while 75% cases of benign thyroid lesion showed positive staining for the same</span></p> <p><strong><span lang="EN-US">CONCLUSION</span></strong><span lang="EN-US">: It was found that CK19 was very specific but less sensitive marker to differentiate benign from malignant neoplasm and CD56 was more sensitive and specific as a marker of benign thyroid lesion. Hence, the use of these markers together could be a useful and reliable diagnostic approach for differentiating malignant from benign thyroid lesions.</span></p> |
| title | UTILIZATION OF CK19 AND CD56 EXPRESSION IN DIFFERENTIATING MALIGNANT FROM BENIGN LESIONS OF THYROID |
| url | https://doi.org/10.5281/zenodo.18066295 |